Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Autologous Stem Cell Transplant Should Remain Standard of Care for Certain DLBCL Patients, Expert Says

Nirav Niranjan Shah, MD

Dr. Nirav Niranjan Shah explains the data behind why autologous stem cell transplant should remain the standard of care for patients with relapsed chemo-sensitive DLBCL.

Evolving Treatment Landscape Presents Patients With Indolent Non-Hodgkin Lymphoma 'Lots of Options'

Conor Killmurray

Dr. Brad S. Kahl discusses the unique challenges that occur when treating patients with indolent non-Hodgkin lymphoma.

Precautions Are Nothing New for Patients with Cancer During COVID-19

Kim Johnson

COVID-19 has dramatically altered the lives of millions across the globe, but for patients with cancer, the new restrictions and new challenges are ones they have already managed to handle.

Making It Personal With Waldenstrom's Macroglobulinemia

Beth Fand Incollingo

Treating relapsed Waldenstrom’s macroglobulinemia takes an individualized approach from a growing list of options.

CURE's Top 5 Stories: July 2019

Jessica Skarzynski

Here are the top 5 CURE stories for July 2019.

What Being a Survivor Means to 'The Pink Hulk', a Three-Time Cancer Survivor

Valerie David

Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE® to discuss life as a survivor.

Blending the Truth With Compassion in Cancer Care

Jerry Bridges, M.S.N., RN, CNP

This essay describes my journey with non-Hodgkin lymphoma — peripheral T-cell, not otherwise specified — and my most extraordinary nurse, Xuan Arnette, RN, OCN.

Friday Frontline: Cancer Updates, Research and Education on July 26, 2019

Alexandra Guadagno

From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.

FDA Approves Biosimilar Ruxience: Here's What You Need to Know

Kristie L. Kahl

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

FDA Approves Rituxan Biosimilar to Treat Blood Cancers

Jessica Skarzynski

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Non-Hodgkin Lymphoma

Sign In